Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients
with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.